Livzon Pharmaceutical Group Inc (SHE:000513) — Market Cap & Net Worth
Market Cap & Net Worth: Livzon Pharmaceutical Group Inc (000513)
Livzon Pharmaceutical Group Inc (SHE:000513) has a market capitalization of $2.56 Billion (CN¥17.49 Billion) as of June 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #5505 globally and #1068 in its home market, demonstrating a -0.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Livzon Pharmaceutical Group Inc's stock price CN¥29.74 by its total outstanding shares 588100054 (588.10 Million). Review Livzon Pharmaceutical Group Inc debt and liabilities to assess the company's total debt and financial obligations.
Livzon Pharmaceutical Group Inc Market Cap History: 2015 to 2026
Livzon Pharmaceutical Group Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.74 Billion to $2.56 Billion (4.41% CAGR).
Livzon Pharmaceutical Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Livzon Pharmaceutical Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.25x
Livzon Pharmaceutical Group Inc's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.47x
Livzon Pharmaceutical Group Inc's market cap is 1.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.82 Billion | $7.65 Billion | $784.35 Million | 0.24x | 2.32x |
| 2017 | $2.66 Billion | $8.53 Billion | $4.43 Billion | 0.31x | 0.60x |
| 2018 | $1.35 Billion | $8.86 Billion | $1.08 Billion | 0.15x | 1.25x |
| 2019 | $2.44 Billion | $9.38 Billion | $1.30 Billion | 0.26x | 1.87x |
| 2020 | $3.02 Billion | $10.52 Billion | $1.71 Billion | 0.29x | 1.76x |
| 2021 | $3.07 Billion | $12.06 Billion | $1.78 Billion | 0.25x | 1.73x |
| 2022 | $2.58 Billion | $12.63 Billion | $1.91 Billion | 0.20x | 1.35x |
| 2023 | $2.90 Billion | $12.43 Billion | $1.95 Billion | 0.23x | 1.49x |
| 2024 | $3.27 Billion | $11.81 Billion | $2.06 Billion | 0.28x | 1.59x |
| 2025 | $2.97 Billion | $11.91 Billion | $2.02 Billion | 0.25x | 1.47x |
Competitor Companies of 000513 by Market Capitalization
Companies near Livzon Pharmaceutical Group Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Livzon Pharmaceutical Group Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Livzon Pharmaceutical Group Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Livzon Pharmaceutical Group Inc's market cap moved from $1.74 Billion to $ 2.56 Billion, with a yearly change of 4.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.56 Billion | -13.70% |
| 2025 | CN¥2.97 Billion | -9.32% |
| 2024 | CN¥3.27 Billion | +12.58% |
| 2023 | CN¥2.90 Billion | +12.38% |
| 2022 | CN¥2.58 Billion | -15.89% |
| 2021 | CN¥3.07 Billion | +1.84% |
| 2020 | CN¥3.02 Billion | +23.71% |
| 2019 | CN¥2.44 Billion | +80.45% |
| 2018 | CN¥1.35 Billion | -49.24% |
| 2017 | CN¥2.66 Billion | +46.28% |
| 2016 | CN¥1.82 Billion | +4.84% |
| 2015 | CN¥1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Livzon Pharmaceutical Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.56 Billion USD |
| MoneyControl | $2.56 Billion USD |
| MarketWatch | $2.56 Billion USD |
| marketcap.company | $2.56 Billion USD |
| Reuters | $2.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more